A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC 330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol

Trial Profile

A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC 330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2013

At a glance

  • Drugs Tanespimycin (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top